company background image
HIK logo

Hikma Pharmaceuticals LSE:HIK Stock Report

Last Price

UK£19.02

Market Cap

UK£4.2b

7D

-3.6%

1Y

-0.9%

Updated

30 Oct, 2024

Data

Company Financials +

Hikma Pharmaceuticals PLC

LSE:HIK Stock Report

Market Cap: UK£4.2b

Hikma Pharmaceuticals PLC Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Hikma Pharmaceuticals
Historical stock prices
Current Share PriceUK£19.02
52 Week HighUK£21.65
52 Week LowUK£17.11
Beta0.41
11 Month Change-0.47%
3 Month Change0.11%
1 Year Change-0.94%
33 Year Change-22.81%
5 Year Change-6.07%
Change since IPO574.47%

Recent News & Updates

Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?

Oct 24
Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?

Hikma Pharmaceuticals PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Aug 11
Hikma Pharmaceuticals PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Recent updates

Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?

Oct 24
Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?

Hikma Pharmaceuticals PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Aug 11
Hikma Pharmaceuticals PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 36% Below Their Intrinsic Value Estimate

Aug 01
Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 36% Below Their Intrinsic Value Estimate

Is Hikma Pharmaceuticals PLC (LON:HIK) Trading At A 29% Discount?

Apr 24
Is Hikma Pharmaceuticals PLC (LON:HIK) Trading At A 29% Discount?

Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?

Apr 02
Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?

Hikma Pharmaceuticals PLC's (LON:HIK) Share Price Matching Investor Opinion

Feb 25
Hikma Pharmaceuticals PLC's (LON:HIK) Share Price Matching Investor Opinion

Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?

Dec 27
Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?

An Intrinsic Calculation For Hikma Pharmaceuticals PLC (LON:HIK) Suggests It's 43% Undervalued

Dec 12
An Intrinsic Calculation For Hikma Pharmaceuticals PLC (LON:HIK) Suggests It's 43% Undervalued

Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet

Sep 19
Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet

Calculating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)

Sep 01
Calculating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)

Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?

Jun 21
Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?

Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 28% Above Its Share Price

Jun 02
Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 28% Above Its Share Price

Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet

Mar 14
Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet

Calculating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)

Feb 21
Calculating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)

Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?

Sep 27
Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?

Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 19% Below Its Share Price

Jun 24
Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 19% Below Its Share Price

These 4 Measures Indicate That Hikma Pharmaceuticals (LON:HIK) Is Using Debt Reasonably Well

Jun 06
These 4 Measures Indicate That Hikma Pharmaceuticals (LON:HIK) Is Using Debt Reasonably Well

Here's Why Hikma Pharmaceuticals (LON:HIK) Can Manage Its Debt Responsibly

Feb 26
Here's Why Hikma Pharmaceuticals (LON:HIK) Can Manage Its Debt Responsibly

Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 92% Above Its Share Price

Dec 01
Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 92% Above Its Share Price

Is Hikma Pharmaceuticals (LON:HIK) Using Too Much Debt?

Nov 11
Is Hikma Pharmaceuticals (LON:HIK) Using Too Much Debt?

Is There An Opportunity With Hikma Pharmaceuticals PLC's (LON:HIK) 32% Undervaluation?

Sep 02
Is There An Opportunity With Hikma Pharmaceuticals PLC's (LON:HIK) 32% Undervaluation?

Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?

Aug 09
Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?

Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 26% Below Their Intrinsic Value Estimate

May 21
Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 26% Below Their Intrinsic Value Estimate

Hikma Pharmaceuticals (LON:HIK) Seems To Use Debt Quite Sensibly

May 03
Hikma Pharmaceuticals (LON:HIK) Seems To Use Debt Quite Sensibly

It's Unlikely That Hikma Pharmaceuticals PLC's (LON:HIK) CEO Will See A Huge Pay Rise This Year

Apr 16
It's Unlikely That Hikma Pharmaceuticals PLC's (LON:HIK) CEO Will See A Huge Pay Rise This Year

How Does Hikma Pharmaceuticals PLC (LON:HIK) Stand Up To These Simple Dividend Safety Checks?

Apr 13
How Does Hikma Pharmaceuticals PLC (LON:HIK) Stand Up To These Simple Dividend Safety Checks?

Hikma Pharmaceuticals PLC (LON:HIK) Looks Interesting, And It's About To Pay A Dividend

Mar 14
Hikma Pharmaceuticals PLC (LON:HIK) Looks Interesting, And It's About To Pay A Dividend

Hikma Pharmaceuticals PLC Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Feb 28
Hikma Pharmaceuticals PLC Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Shareholder Returns

HIKGB PharmaceuticalsGB Market
7D-3.6%-4.7%-1.1%
1Y-0.9%5.6%10.2%

Return vs Industry: HIK underperformed the UK Pharmaceuticals industry which returned 8.7% over the past year.

Return vs Market: HIK underperformed the UK Market which returned 11.1% over the past year.

Price Volatility

Is HIK's price volatile compared to industry and market?
HIK volatility
HIK Average Weekly Movement3.6%
Pharmaceuticals Industry Average Movement7.0%
Market Average Movement4.8%
10% most volatile stocks in GB Market9.4%
10% least volatile stocks in GB Market2.6%

Stable Share Price: HIK has not had significant price volatility in the past 3 months compared to the UK market.

Volatility Over Time: HIK's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19789,100Riad Mishlawiwww.hikma.com

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.

Hikma Pharmaceuticals PLC Fundamentals Summary

How do Hikma Pharmaceuticals's earnings and revenue compare to its market cap?
HIK fundamental statistics
Market capUK£4.22b
Earnings (TTM)UK£219.74m
Revenue (TTM)UK£2.33b

19.2x

P/E Ratio

1.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HIK income statement (TTM)
RevenueUS$3.02b
Cost of RevenueUS$1.57b
Gross ProfitUS$1.45b
Other ExpensesUS$1.16b
EarningsUS$285.00m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)1.29
Gross Margin47.99%
Net Profit Margin9.45%
Debt/Equity Ratio53.2%

How did HIK perform over the long term?

See historical performance and comparison

Dividends

3.2%

Current Dividend Yield

61%

Payout Ratio